title: A single-center retrospective analysis of liver transplantation on 255 patients with hepatocellular carcinoma.
abstract: BACKGROUND
  Liver transplantation (LT) was advocated as a salvage treatment of choice for patients with unresectable hepatocellular carcinoma (HCC). This study was designed to assess the eligibility of LT criteria for patients with HCC and to analyze the factors influencing the recurrence of HCC following LT, aiming to further improve the efficacy of LT for patients with HCC.
  
  
  METHODS
  Clinical data of 255 patients with HCC who underwent LT between December 2001 and December 2007 at Shanghai Changzheng Hospital, China were retrospectively analyzed.
  
  
  RESULTS
  Among these cases, 75 patients were within the Milan criteria and 180 were beyond it; 110 patients were within the University of California, San Francisco (UCSF) criteria, while 145 were beyond it. The difference in overall survival rates was not only significant between the patients within and beyond the Milan criteria but also between patients within and beyond the UCSF criteria. Tumor-node-metastasis (TNM) staging, portal vein tumor thrombus (PVTT), and the pre-operative alpha-fetoprotein (AFP) level were independent risk factors affecting the overall survival and post-operative recurrence-free survival rates of patients with HCC. Pathological staging and pre-operative local treatment of HCC had no obvious correlation with the post-operative recurrence-free survival rate.
  
  
  CONCLUSIONS
  LT is an effective treatment modality for HCC. The UCSF criteria did not show better effectiveness than the Milan criteria. TNM staging, PVTT, and the pre-operative AFP level are closely related to the recurrence of HCC following LT.
authors.affiliation: Organ Transplantation Center, Changzheng Hospital, Second Military Medical University, Shanghai, China University of Arkansas for Medical Sciences, Shanghai, China.
authors.forename: Zheng-Xin
authors.initials: ZX
authors.lastname: Wang
authors.forename: Shao-Hua
authors.initials: SH
authors.lastname: Song
authors.forename: Fei
authors.initials: F
authors.lastname: Teng
authors.forename: Gui-Hua
authors.initials: GH
authors.lastname: Wang
authors.forename: Wen-Yuan
authors.initials: WY
authors.lastname: Guo
authors.forename: Xiao-Min
authors.initials: XM
authors.lastname: Shi
authors.forename: Jun
authors.initials: J
authors.lastname: Ma
authors.forename: You-Min
authors.initials: YM
authors.lastname: Wu
authors.forename: Guo-Shan
authors.initials: GS
authors.lastname: Ding
authors.forename: Zhi-Ren
authors.initials: ZR
authors.lastname: Fu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000601:surgery*; D005260:Female; D006085:Graft Survival; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D016879:Salvage Therapy; D015996:Survival Rate; D055815:Young Adult